- Home
- NUWE vs PRFX Comparison
NUWE vs PRFX Comparison
Compare NUWE & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUWE | PRFX |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NUWE | PRFX |
|---|---|---|
| Price | $1.90 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 91.3K | ★ 343.3K |
| Earning Date | 11-12-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,167,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $0.61 |
| 52 Week High | $70.14 | $6.65 |
Technical Indicators
Market Signals| Indicator | NUWE | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 68.03 |
| Support Level | $1.88 | $0.77 |
| Resistance Level | $2.85 | $0.92 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 14.55 | 55.06 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.